Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.35 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9354591 | 0.92 | USP2 (0.47) | USP2LMNAALDH1A1KDM4ETDP1 | |
| Isopropyl Alcohol SCHEMBL7787253 | 0.89 | USP2 (0.52) | USP2LMNAALDH1A1KDM4ETDP1 | |
| Isobutane SCHEMBL27997158 | 0.89 | USP2 (0.52) | USP2LMNAALDH1A1KDM4ETDP1 | |
| SCHEMBL5198804 | 0.88 | USP2 (0.48) | USP2LMNAALDH1A1KDM4ETDP1 | |
| SCHEMBL18070867 | 0.87 | USP2 (0.44) | USP2LMNAALDH1A1KDM4EHSD17B10 | |
| Propylene Glycol SCHEMBL2236346 | 0.86 | TDP1 (0.56) | USP2LMNAALDH1A1KDM4ETDP1 | |
| Ethane SCHEMBL2303498 | 0.86 | USP2 (0.54) | USP2LMNAALDH1A1KDM4ETDP1 | |
| Methyl Alcohol SCHEMBL27869223 | 0.86 | USP2 (0.54) | USP2LMNAALDH1A1KDM4ETDP1 | |
| SCHEMBL1638881 | 0.86 | LMNA (0.53) | USP2LMNAALDH1A1KDM4ETDP1 | |
| SCHEMBL30754 | 0.86 | LMNA (0.53) | USP2LMNAALDH1A1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180074066-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2018-03-15 | — | — | US | disclosed |
| US-20180074067-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2018-03-15 | — | — | US | disclosed |
| US-20160349267-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN GROUP LIMITED (GB) | 2016-12-01 | — | — | US | disclosed |
| EP-3067381-A1 | Coated silicon surfaces, their manufacture and application | BASF SE (DE) | 2016-09-14 | — | — | EP | disclosed |
| US-9139869-B2 | Reagents for directed biomarker signal amplification | SIRIGEN INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140206557-A1 | Novel Reagents for Directed Biomarker Signal Amplification | SIRIGEN INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8362193-B2 | Reagents for directed biomarker signal amplification | SIRIGEN GROUP LIMITED (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362193-B2 | Reagents for directed biomarker signal amplification | SIRIGEN GROUP LIMITED (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20100247458-A1 | Emulsified External Skin Preparations | SHISEIDO CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| WO-2010000713-A1 | LINEAR-DENDRITIC POLYGLYCEROL COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF | FREIE UNIVERSITÄT BERLIN (DE) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180074066-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | USP2 1631/4885LMNA 1915/4885ALDH1A1 2146/4885 |
| US-20160349267-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | USP2 1631/4885LMNA 1915/4885ALDH1A1 2146/4885 |
| US-20100247458-A1 | Emulsified External Skin Preparations | CUTA, DEGS1, H1-0 | USP2 1541/4885LMNA 1745/4885ALDH1A1 3826/4885 |
| US-20180074067-A1 | Novel Reagents for Directed Biomarker Signal Amplification | RNGTT, CAPG, CD2BP2 | USP2 1631/4885LMNA 1915/4885ALDH1A1 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.